Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth Signs Clinical Trial Partnership With Japan's Largest Hospital Network

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Wyeth's fully owned Japanese subsidiary signed a clinical trial partnership agreement with National Hospital Organization, the Japanese government body that manages most national hospitals, becoming the first pharmaceutical maker clinching such an accord with the largest hospital network in the country, Wyeth K.K. spokesman Ken Takashima said July 7

You may also be interested in...

Eisai Plans R&D Structure Revamp, Hoping To Turn The Development Tide

TOKYO - Eisai CEO Haruo Naito unveiled plans to revamp the company's research and development structure in hopes of having his employees produce better results, Naito told analysts Feb. 27 in Tokyo

Japanese Pharma Looking Beyond Japan For Clinical Trials

TOKYO - Japanese pharmaceutical manufacturers are diversifying their Phase III clinical trials away from Japan to establish development footholds into fast-developing East Asia and other regions where costs are low and trial patients can be secured with ease

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts